90. 網膜色素変性症 Retinitis pigmentosa Clinical trials / Disease details
臨床試験数 : 130 / 薬物数 : 180 - (DrugBank : 41) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 109
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01482195 (ClinicalTrials.gov) | August 2011 | 28/9/2011 | Trial of Subretinal Injection of (rAAV2-VMD2-hMERTK) | Phase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients With Retinal Disease Due to MERTK Mutations | Retinal Disease;Retinitis Pigmentosa | Biological: Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus | King Khaled Eye Specialist Hospital | King Faisal Specialist Hospital & Research Center | Completed | 14 Years | 70 Years | All | 6 | Phase 1 | Saudi Arabia |